Bay Area biotech firm once worth more than $4B lays off 30% of staff
ALX Oncology, a Bay Area biotech firm currently running clinical trials for its anticancer therapy, announced Wednesday that it’s laying off about 30% of its staff. ALX shared the news in a press ...
Fierce Biotech9d
ALX lays off 30% of staff to pay for more trials of CD47 blocker
ALX Oncology is laying off 30% of its workforce as the biotech seeks to channel its cash into further trials of its CD47 ...
Yahoo Finance7d
Why ALX Oncology Holdings Inc. (ALXO) Soared on Thursday
Looking ahead, ALX Oncology Holdings Inc. (NASDAQ:ALXO) CEO Jason Lettmann said that its multiple ongoing clinical studies are set to position the company for near- and long-term success.
GlobalData on MSN6mon
Greenridge intends to acquire ALX Resources
ALX CEO Warren Stanyer will join Greenridge as president and director. The merger is also expected to yield significant cost ...
Nasdaq8d
ALX Oncology Cuts 30% Workforce, Eliminates President And CSO Role Amid Pipeline Prioritization
(RTTNews) - ALX Oncology Holdings Inc. (ALXO), a biopharmaceutical company focused on oncology treatments, has announced a workforce reduction of approximately 30% as part of its strategy to ...